SOT-201 is under clinical development by SOTIO Biotech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SOT-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SOT-201 overview
SOT-201 is under development for the treatment of metastatic solid tumor. It is an immunocytokine that acts by targeting interleukin 15 receptor and programmed cell death factor 1 (PD1). SO-C108 is an immunocytokine fusing SO-C101 to pembrolizumab to directly target T cells. It is administered through intravenous route.
SOTIO Biotech overview
SOTIO Biotech (Sotio), a subsidiary of PPF Group NV, is a biotechnology company that develops immunotherapies for cancer treatment. It also evaluates IL-15, superagonist-based programs to develop immunotherapies in oncology. Sotio utilizes its proprietary BOXR cell therapy platform to design and develop engineered T cells by identifying novel bolt-on transgenes in the solid tumor microenvironment. The company is investigating SOT201, an immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody; and BOXR1030, CART T cell therapy against hepatocellular carcinoma and squamous cell carcinoma. The company has operations in Switzerland, the Czech Republic, the Netherlands, and the US. Sotio is headquartered in Prague, North Bohemian, the Czech Republic.
For a complete picture of SOT-201’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
